Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · Real-Time Price · USD
558.87
+13.41 (2.46%)
At close: Aug 1, 2025, 4:00 PM
561.00
+2.13 (0.38%)
After-hours: Aug 1, 2025, 7:34 PM EDT
2.46%
Market Cap57.95B
Revenue (ttm)14.21B
Net Income (ttm)4.46B
Shares Out 103.69M
EPS (ttm)39.67
PE Ratio14.09
Forward PE14.61
Dividend$3.52 (0.65%)
Ex-Dividend DateMay 20, 2025
Volume1,656,296
Open583.01
Previous Close545.46
Day's Range542.89 - 583.28
52-Week Range476.49 - 1,211.20
Beta0.33
AnalystsBuy
Price Target823.86 (+47.42%)
Earnings DateAug 1, 2025

About VERV

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 2, 1991
Employees 15,106
Stock Exchange NASDAQ
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial Statements

Analyst Summary

According to 21 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $823.86, which is an increase of 47.42% from the latest price.

Price Target
$823.86
(47.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Regeneron: Rapidly Decreasing Importance Of Eylea

Regeneron Pharmaceuticals delivered strong Q2 results, driven by Dupixent and Libtayo growth that were enough to offset the decline of the Eylea franchise. The existing product portfolio and upcoming ...

15 hours ago - Seeking Alpha

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO George D.

18 hours ago - Seeking Alpha

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

19 hours ago - WSJ

US FDA declines to approve Regeneron's blood cancer therapy for second time

Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, this time in relation to observations from the regulator's inspection at a t...

21 hours ago - Reuters

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

23 hours ago - CNBC Television

Regeneron beats second-quarter results estimates on Dupixent sales boost

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up nearl...

23 hours ago - Reuters

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

1 day ago - CNBC Television

Regeneron Reports Second Quarter 2025 Financial and Operating Results

TARRYTOWN, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update.

1 day ago - GlobeNewsWire

Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Regeneron Pharmaceuticals, Inc. REGN will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.

1 day ago - Benzinga

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...

1 day ago - Forbes

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.

1 day ago - CNBC Television

Trump pressures 17 pharma CEOs to cut US drug prices

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...

1 day ago - Reuters

Trump posts letters to 17 pharmaceutical companies about drug prices

CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.

1 day ago - CNBC Television

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...

1 day ago - CNBC

5 Stocks That Launched New Dividends In This Roller-Coaster Market

Brand new dividends are often the best divvies to buy. Here why.

Other symbols: MRPVTOLWDCWSC
3 days ago - Forbes

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron...

9 days ago - GlobeNewsWire

Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Reg...

22 days ago - Seeking Alpha

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

4 weeks ago - WSJ

US FDA approves Regeneron's blood cancer therapy

The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood ...

4 weeks ago - Reuters

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday,...

5 weeks ago - GlobeNewsWire

Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade

Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robu...

5 weeks ago - Seeking Alpha

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications Initiative aims to expand and encourage philanthropy to help patients with retinal ...

5 weeks ago - GlobeNewsWire

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

5 weeks ago - CNBC Television

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the elderly and is characterized by itchiness, blisters and lesions.

Other symbols: SNY
6 weeks ago - WSJ

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

6 weeks ago - GlobeNewsWire